BREAST CARCINOMA IN SITU
Clinical trials for BREAST CARCINOMA IN SITU explained in plain language.
Never miss a new study
Get alerted when new BREAST CARCINOMA IN SITU trials appear
Sign up with your email to follow new studies for BREAST CARCINOMA IN SITU, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy after chemo shows promise for aggressive breast cancer
Disease control OngoingThis phase 3 trial tests whether adding the immunotherapy drug pembrolizumab after standard chemotherapy helps prevent triple-negative breast cancer from returning. About 1,155 patients with residual cancer after chemo are randomly assigned to receive pembrolizumab or a placebo. …
Matched conditions: BREAST CARCINOMA IN SITU
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New combo may help women with early breast cancer avoid mastectomy
Disease control ENROLLING_BY_INVITATIONThis study tests whether giving two cancer drugs (trastuzumab and a taxane) before surgery can shrink HER2-positive breast carcinoma in situ tumors enough to allow breast-conserving surgery instead of full breast removal. About 54 women aged 18-70 with tumors at least 2 cm will r…
Matched conditions: BREAST CARCINOMA IN SITU
Phase: PHASE2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New gel could fight breast cancer before surgery
Disease control OngoingThis early-stage trial tests a gel form of the drug endoxifen on women scheduled for breast surgery. The goal is to find the safest dose and see if it can treat or lower the risk of breast cancer. About 32 women with various stages of breast cancer or high risk will apply the gel…
Matched conditions: BREAST CARCINOMA IN SITU
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:52 UTC